El-Sharkawi, D; Ng, C-H; Payne, EMC; Yong, KL; Ardeshna, KM; Khwaja, A; Townsend, W; El-Sharkawi, D; Ng, C-H; Payne, EMC; Yong, KL; Ardeshna, KM; Khwaja, A; Townsend, W; Popat, R; - view fewer (2019) Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. British Journal of Haematology , 185 (2) pp. 344-347. 10.1111/bjh.15457.

Preview

Text Payne_post acceptance.pdf - Accepted Version Download (117kB) | Preview

Abstract

Phase I clinical trials are primarily designed to assess the safety and toxicity of a new agent and determine the recommended dose for further trials that assess efficacy. Patients entering these trials typically have multiply relapsed or refractory disease and would otherwise receive supportive treatment. The collective outcomes of patients enrolled onto phase I trials in solid tumors but not in hematological malignancies have previously been reported. We analyzed the overall outcomes and survival of 91 patients enrolled onto one of 14 Phase I and I/II trials for hematological malignancies at a dedicated early phase trials unit within a tertiary hematology unit. Median time on trial was 3.7 months (range 0-24), 32% experienced grade 3 or 4 adverse events. The overall response rate was 41%, overall survival 18 months (95% confidence intervals 5-30 months) and progression free survival 7 months (95% CI 1-13), although there was a significant difference according to underlying hematological cancer subtype. Response rate was strongly associated with survival time. On multivariate analysis, disease subtype and LDH at time of trial entry showed an association with survival rate. These results demonstrate that the outcomes of patients with hematiological malignancies entering phase I trials is better than expected.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item